若生智能
Drug Database
AS

AS0-3B (AS03B1 / AS03B)

✓ Approved

GSK · 治疗药物

什么是 AS0-3B？

AS0-3B 是一种治疗药物，由GSK研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名AS03B1, AS03B
公司GSK
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, GSK

治疗适应症

AS0-3B 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedTAG. Theoretical and applied genetics. Theoretische und angewandte Genetik2026-07-27

Identification of stripe rust resistance loci in Gansu wheat landraces using genome-wide association analysis.

Zhang Zhe Z, Zhang Yu Y, Guo Ying Y, Ye Xinyi X et al.

Stripe rust severely threatens global wheat production. Identifying and using favorable resistance loci from landraces can increase the genetic diversity and durability of resistance in modern wheat cultivars. In this study, we phenotyped 376 wheat landraces from Gansu for stripe rust resistance through seedling inoculation with race CYR34 and multiyear field trials across six environments. Genotyping was performed using a 16 K SNP array and known gene markers. In total, seven significant quantitative trait loci located on chromosomes 2A, 2D, 3B, 3D, 4B, and 7A were detected at the seedling stage. Four significant and stable QTLs, including the known pleiotropic adult plant resistance gene Yr18, were identified at the adult plant stage. Among them, Yr.hzau.4B was stably detected at both ASR and APR, explaining 9.46% and 11.58% of the phenotypic variation, respectively. Haplotype analysis revealed that, compared with materials carrying the unfavorable haplotype, wheat landraces harboring the favorable Yr.hzau.4B haplotype presented a reduction of 0.6 grading units in the average infection type for ASR and a 32.4% decrease in DS for APR. Additive interaction analysis further indicated a decreasing trend in both IT and DS with an increasing number of favorable haplotypes. Additionally, a KASP molecular marker for Yr.hzau.4B was developed and validated in an independent population. Integrated candidate gene analysis revealed 29 putative resistance-related genes, encompassing gene families such as kinases and transporters. This study identified new resistance gene loci and developed breeder-friendly molecular markers. These compounds can be used to improve stripe rust resistance in wheat and provide useful resources for the breeding of wheat resistance.

PMID 42506996
阅读全文 →
PubMedMedical sciences (Basel, Switzerland)2026-07-27

Arthroscopy-Assisted Core Decompression Combined with Octacalcium Phosphate/Gelatin Composite Implantation for Osteonecrosis of the Femoral Head: A Study Protocol for a Single-Center Externally Controlled Trial.

Tanaka Hidetatsu H, Baba Kazuyoshi K, Kanabuchi Ryuichi R, Kuriyama Yasuaki Y et al.

Background/Objectives: Osteonecrosis of the femoral head is a progressive disease that frequently leads to femoral head collapse and secondary osteoarthritis. Although total hip arthroplasty provides reliable outcomes, its use in younger patients is limited due to concerns regarding implant longevity. Joint-preserving procedures such as core decompression have been widely used; however, their efficacy remains controversial. This study aims to evaluate a combined approach using arthroscopy-assisted core decompression and an osteoconductive bone substitute. Methods: This study is designed as a single-center, externally controlled trial conducted at Tohoku University Hospital. Patients with osteonecrosis of the femoral head (Japanese Investigation Committee Stage 1-3B, Type B-C2) will undergo arthroscopy-assisted core decompression combined with octacalcium phosphate/gelatin composite implantation. A total of 25 patients will be prospectively enrolled. Outcomes will be compared with a propensity score-matched historical control cohort. The primary outcome is disease progression within 1 year, defined as radiographic progression or conversion to total hip arthroplasty. Secondary outcomes include radiographic changes, clinical outcomes, and bone remodeling assessed by computed tomography. Expected Results: This study is expected to provide preliminary clinical evidence regarding the feasibility and potential effectiveness of arthroscopy-assisted core decompression combined with octacalcium phosphate/gelatin composite implantation for osteonecrosis of the femoral head. The intervention may promote bone remodeling and contribute to the prevention of femoral head collapse. Conclusions: The findings of this study may contribute to the development of improved minimally invasive joint-preserving treatment strategies for osteonecrosis of the femoral head and provide a basis for future large-scale clinical trials.

PMID 42506307
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-07-27

Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).

Rodbard Helena W HW, Irace Concetta C, Lobo Jevitha J, Makrilakis Konstantinos K et al.

Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once-weekly semaglutide 2.0 mg as add-on to dose-reduced insulin glargine (Sema+IGlarreduced) versus dose-titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and participant satisfaction. SUSTAIN OPTIMIZE was a 40-week, phase 3b, open-label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m2), and treatment with basal insulin ≤ 40 units/day were randomised 1:1 into Sema+IGlarreduced or IGlartitrated. The primary endpoint was change in HbA1c using a non-inferiority approach. Secondary endpoints assessed superiority of Sema+IGlarreduced versus IGlartitrated in reducing HbA1c, BW, daily insulin dose, and improving Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scores. Overall, 573 participants were randomised. Sema+IGlarreduced achieved both non-inferiority and superiority versus IGlartitrated in HbA1c reduction (estimated treatment difference [ETD]: -0.74%; 95% confidence interval [CI95]: -0.90, -0.59) and superiority in BW change (ETD: -8.5 kg; CI95: -9.5, -7.4), relative daily insulin dose change (ETD: -121.9%; CI95: -143.1, -100.6), and DTSQc scores (ETD: 2.6; CI95: 1.6, 3.5) (p < 0.0001 for all endpoints). No new safety concerns were identified. Severe hypoglycaemia was reduced (rate ratio: 0.45; CI95: 0.23, 0.87; p = 0.02), while gastrointestinal events were higher for Sema+IGlarreduced (310 vs. 32 events). Once-weekly subcutaneous semaglutide 2.0 mg as add-on to dose-reduced IGlar achieved superior reductions in HbA1c, BW, and daily insulin dose in people with T2D and overweight, while reducing their risk for severe hypoglycaemia compared to dose-titrated IGlar alone.

PMID 42504064
阅读全文 →
PubMedNuclear medicine and molecular imaging2026-07-26

Evaluating Locally Deployed Large Language Models for Ga-68 PSMA PET/CT Report Mining in Prostate Cancer.

Chaudhary Jagrati J, Sharma Param Dev PD, Kumar Sanjay S, Takalkar Nikita N et al.

Large Language Models (LLMs) extracts structured data from unstructured Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA PET/CT) reports by interpreting context and semantics, enabling reliable conversion of free-text into structured, queryable data. We evaluated whether locally deployed Llama 3.2:3b and Gemma 2:2b models could accurately perform zero-shot extraction of key diagnostic features. We retrospectively selected 50 de-identified Ga-68 PSMA PET/CT reports of histologically confirmed prostate cancer (01 January 2020-30 June 2024), ensuring rigorous expert annotation and inter-reader agreement. Reports were batch-processed using standardized zero-shot and few-shot prompts applied to locally deployed Llama 3.2:3b and Gemma 2:2b models, with model outputs benchmarked against an adjudicated dual-expert ground truth reference derived from independent annotations and consensus resolution of discrepancies using standard performance metrics. Both Llama 3.2:3b and Gemma 2:2b achieved rapid, reliable extraction of key diagnostic features from Ga-68 PSMA PET/CT reports, with excellent inter-reader agreement (average κ = 0.882). Llama 3.2:3b offered superior sensitivity (83.7%) and negative predictive value (NPV) (97.3%), while Gemma 2:2b demonstrated greater overall accuracy (86.2%) and specificity (88.5%). Model performance varied with question prevalence and complexity, highlighting distinct strengths for clinical integration. Open-weight Llama 3.2:3b and Gemma 2:2b LLMs enable rapid extraction of key PET/CT findings (16-20x faster than manual review), with Llama excelling in sensitivity and Gemma in specificity. However, modest performance on rare but clinically important findings and limited positive predictive value indicate these models are best suited for initial screening or human-assisted workflows rather than autonomous extraction. The online version contains supplementary material available at 10.1007/s13139-026-00991-z.

PMID 42502653
阅读全文 →
PubMedChemistry, an Asian journal2026-07-26

Spin State Dependent Reactivity of Iron-Nitrosyls With Dioxygen.

Ghosh Riya R, Guha Ankur K AK, Mondal Biplab B

Two iron nitrosyls, 2a and 2b, having {Fe(NO)}7 configuration but different spin states have been synthesized in Pz2Py [Pz2Py = bis(di(3,5-dimethyl-1H-pyrazolyl)methyl)-(2-pyridylmethyl)amine] ligand framework and have been characterized spectroscopically. In addition, the high-spin nitrosyl complex, 2a was also characterized structurally. FT-IR studies show that the nitrosyl stretching, νNO appears at 1790 and 1711 cm-1 for high-spin and low-spin analogues, respectively. The dioxygen reactivity of complexes 2a and 2b have been explored. The high-spin complex, 2a was found to react spontaneously with O2, leading to the formation of the corresponding nitrate (NO3‾) product, 3a through a presumed peroxynitrite intermediate. In contrast, dioxygen substitutes the NO group from complex 2b, owing to the weaker Fe-NNO bond, resulting in the formation of [FeIII(Pz2Py)(OH)(CH3CN)](ClO4)2, 3b. The release of NO by O2, in this case, was evident from the presence of NO2 in the GC-Mass of the headspace gas from the reaction vessel.

PMID 42502256
阅读全文 →
PubMedRSC advances2026-07-25

Synthesis and in vitro antiproliferative activity of dolutegravir derivatives against hepatocellular carcinoma via apoptosis-related mechanisms.

Hou Xixi X, Huang Mengmeng M, Zhang Qingqing Q, Yao Qiyan Q et al.

Drug repurposing through structural modification of marketed drugs is a well-established strategy for the discovery of novel therapeutic agents, benefiting from known safety profiles and clinical relevance. Dolutegravir, a widely used HIV integrase inhibitor featuring a nitrogen-oxygen heterocycle, provides an attractive scaffold for exploring new pharmacological activities. In this study, a series of novel dolutegravir derivatives bearing 1,2,3-triazole moieties were synthesized via click chemistry and evaluated for their antitumor activity against hepatocellular carcinoma (HCC). Among them, compounds 3b and 3i exhibited potent antiproliferative activity against HepG2 cells, with IC50 values of 7.89 µM and 15.07 µM, respectively. Both compounds also showed significant inhibitory activity against Huh7 cells, with IC50 values of 2.94 µM for 3b and 4.69 µM for 3i. Further biological studies demonstrated that compounds 3b and 3i significantly induced apoptosis in HepG2 cells, inhibited cell migration in wound-healing assays, and suppressed colony formation. Mechanistic investigations in Huh7 cells further revealed that compound 3b induced concentration-dependent cell death and apoptosis, accompanied by enhanced autophagy and DNA damage. These antitumor effects were associated with significant alterations in apoptosis- and migration-related protein expression. Collectively, these findings demonstrate that dolutegravir-based 1,2,3-triazole derivatives possess promising anti-hepatocellular carcinoma activity and identify compound 3b as a potential lead candidate for further anticancer drug development.

PMID 42500415
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AS0-3B